Recruiting

Long-term tracking of a heat vapor lung treatment for emphysema

Plain-English translation of NCT03318406 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This trial is a registry—a long-term tracking study—for patients with emphysema who are being treated with InterVapor, a procedure that uses heat vapor to shrink damaged lung tissue. Researchers will follow you for five years after your treatment to see how well it works and whether you experience any side effects. The goal is to gather real-world information about this treatment's safety and effectiveness.

Emphysema damages the lungs and makes it hard to breathe. This treatment is a newer option for patients who haven't improved enough with medicines alone, and this registry exists to understand how well this medication works over the long term and what risks patients should be aware of.

Do you qualify?

You likely qualify if…

you have been diagnosed with emphysema that is worse in the upper parts of your lungs
you are at least 18 years old
you are planning to receive or have received the InterVapor heat vapor treatment
you are willing to provide informed consent and participate in follow-up visits

You likely don't qualify if…

you have very severe lung damage (FEV1 or DLCO less than 20% of normal)
you cannot walk more than 140 meters in six minutes, even after optimizing your medicines
you have had more than 3 COPD-related hospital stays in the past year or a recent hospitalization in the past 3 months
you have a history of asthma, severe bleeding disorders, unstable heart disease, or immune system disorders
you are pregnant, breastfeeding, or have had a recent respiratory infection or COPD flare-up in the past 6 weeks

What participation looks like

You will be followed as part of standard care for five years after your InterVapor treatment. During this time, you'll have regular appointments to measure your lung function through breathing tests, walk tests, chest imaging (X-rays and CT scans), and quality of life questionnaires. Researchers will track any side effects or complications and work with doctors to ensure all safety information is carefully recorded and reviewed.

AI-generated summary from trial data · Jun 8, 2026 · Not medical advice

Trial locations(20 sites)

Austria

Krankenhaus Nord - Klinik Floridsdorf, Vienna

Germany

Sozialstiftung Bamberg, Klinikum am Bruderwald, Bamberg

DRK Kliniken Berlin / Mitte, Berlin

FORSCHUNGSINSTITUT Havelhöhe gGmbH, Berlin

Ruhrlandklinik - Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen